Given the multifaceted advantages of large volume wearable injectors, the field has witnessed an increase in the number of players involved in the development of such devices. The domain features the presence of over 35 companies which are involved in the development of over 70 large volume wearable injectors for the delivery of insulin and non-insulin drugs.
Majority of the developers (35%) of large volume wearable injectors and drug-device combinations involved in the delivery of non-insulin drugs are start-ups or small-sized (less than 50 employees), followed by 26% large (501-5000 employees) and 22% very large companies (above 5000 employees). Examples of very large companies include (in alphabetical order, established before 2000) 3M, Amgen, Becton Dickinson, Roche and West Pharmaceutical Services.
Devices developed for administration of non-insulin drugs have high storage capacities and are designed for either bolus or extended dosing of highly viscous formulations. In fact, around 65% of such devices have capacity to hold 6-10 mL of drug / therapy formulation, while 23% have storage capacity of more than 10 mL. In addition, some devices, such as Enable Injection’s enFuse™ On-Body Infusor and Enable Smart enFuse™ can hold up to 50 mL drug solution.
Further, more than 15 drug device combinations are marketed / being evaluated for delivery of non-insulin drugs. Examples of combination products that are being evaluated in clinical trials include (in alphabetical order, no selection criteria) FUROSCIX® On-Body Infusor (scPharamaceuticals), ND0701 (Neuroderm), and The LUTREPULSE® System (Insulet / Ferring Pharamecuticals).
It is worth highlighting that majority (48%) of the stakeholders engaged in this domain are based in Europe, followed by North America and Asia-Pacific.
There are close to 35 devices for insulin delivery that are either approved / marketed (53%) or under development by close to 18 players. The domain is comparatively more established for the delivery of insulin with innovation being primarily led by the devices’ integration to continuous blood monitoring (CGM) systems and advanced algorithms which can automate the insulin dose delivery based on the patient’s blood glucose levels. MiniMed™ 670G Insulin Pump Sytem (Medtronic) and t:slim X2™ Insulin Pump (Tandem Diabetes) are notable examples of marketed devices which can automate the insulin delivery to variable extends.
Further, 53% of the insulin-delivering large volume wearable injectors are patch-pumps. These can be worn directly on the patients’ body, with the help of an adhesive and don’t require a separate infusion set.